![](/wp-content/uploads/2024/06/Screenshot-2024-06-07-at-1.32.44%E2%80%AFPM.png)
$599
BI Presents MASH Data at EASL 2024; Scholar Rock Initiates Ph2 Apitegromab Trial in Obesity; Biomea’s BMF-219 Placed on Clinical Hold
Three cardiometabolic-related news items have been observed: Boehringer Ingelheim announced full results from its Ph2 survodutide MASH trial were presented at the EASL 2024 conference (view press release); Scholar Rock’s Ph2 apitegromab obesity trial has been posted to CT.gov (view CT.gov record); and Biomea Fusion’s BMF-219 trials have been placed on clinical hold due to an increase in liver enzymes observed in the Ph1/2 trial (view press release). Below, FENIX provides highlights and insights into the respective news items.